PharmEnable Closes $7.5M Financing led by MP Healthcare to Develop Next Generation of Small Molecule Drugs to Treat Cancer and Neurological Diseases
- $7.5M Pre-Series A financing led by new investor MP Healthcare, the venture arm of Mitsubishi Tanabe Pharma Group. Existing investors Cambridge Enterprise, University of Cambridge Enterprise Fund VIII, managed by Parkwalk Advisors Heyford Trust, o2h Ventures, Martlet Capital, Arrowfield Capital, Wren Capital and experienced life sciences angel investors including Jonathan Milner also participated
- PharmEnable has developed a proprietary drug discovery platform that focuses on chemical novelty, diversity and 3-dimensionality
- Funds will allow PharmEnable to advance and expand its portfolio of wholly owned and co-discovery projects around challenging targets in cancer and neurology
- Expanded Board of Directors includes Dr Jeffrey Moore and Dr Keith Blundy, both of whom bring significant biotech and pharmaceutical industry experience
CAMBRIDGE, United Kingdom, May 22, 2023 (GLOBE NEWSWIRE) -- PharmEnable, a drug discovery company focused on chemical novelty, diversity and complexity, announces it has closed a Pre-Series A investment round of $7.5M to develop the next generation of small molecule drugs against disease areas of high clinical need.
The funding round was led by MP Healthcare Venture Management (MPH), the venture arm of Mitsubishi Tanabe Pharma Group, with additional participation from existing investors including Cambridge Enterprise, the commercialisation arm of the University of Cambridge, University of Cambridge Enterprise Fund VIII, managed by Parkwalk Advisors, Heyford Trust, o2h Ventures, Martlet Capital, Arrowfield Capital, Wren Capital and life science experienced angel investors including Jonathan Milner.
The funds will be used to advance and expand PharmEnable’s portfolio of wholly owned and co-discovery projects across oncology and neurology targets, as well as supporting further platform R&D.
PharmEnable uses its proprietary platform to discover targeted therapies with the aim of replicating the specificity of biologics, but with improved efficacy, absorption and distribution properties enabled by custom-designed oral small molecules, which are also easier to scale and manufacture. The Company’s approach combines advanced medicinal chemistry with state-of-the-art AI technology, allowing it to unlock challenging biological targets by mapping unexplored chemical space. This approach delivers novel proprietary candidate drug molecules with the required 3-dimensional structure elements that lead to improved selectivity and ultimately reduce attrition rates. The aim is to develop therapies that are highly effective with fewer side effects to treat diseases with a high clinical need.
PharmEnable has a pipeline of wholly owned oncology programmes, as well as ongoing co-discovery projects with several pharma and biotech companies, including a partnership with Sosei Heptares to unlock novel drug candidates for neurological disease. The wholly owned programmes focus on addressing some of the key challenges in oncology such as tumour penetration and overcoming resistance mechanisms, through designing novel, complex small molecules with improved selectivity and carefully balanced properties.
Alongside the investment, PharmEnable’s Board has been expanded with Dr Jeffrey Moore joining as a Board Director, representing MP Healthcare. Dr Keith Blundy has replaced Dr Christine Martin as an Investor Director on behalf of Cambridge Enterprise. Both bring significant pharma and biotech experience.
Dr Jeffrey Moore is President of MP Healthcare and has been working in the biotech sector for 25 years, both as an investor and in operating roles at Millennium Pharmaceuticals and Scriptgen. Until recently Dr Keith Blundy was the CEO of STORM Therapeutics and prior to that Chief Executive of Cancer Research Technology Ltd (CRT), the commercial arm of Cancer Research UK. He was formerly a director of KuDOS Pharmaceuticals Ltd, Mission Therapeutics, Cancer Therapeutics Pty and Inivata Ltd.
CEO of PharmEnable Dr Hannah Sore said, “At PharmEnable, we believe that everyone deserves safe and effective treatments, and we are committed to applying the principles chemical novelty, diversity and 3-dimensionality to design powerful new small molecule drugs.I am delighted that MP Healthcare has led our Pre-Series A to enable our mission to deliver life-changing medicines to patients who need them.
“I am pleased to welcome the highly experienced Dr Jeffrey Moore and Dr Keith Blundy to our Board and look forward to working our team, our Board and our investors to deliver novel therapeutics for the most challenging disease areas, ultimately making a difference to patients’ lives.”
Dr Jeffrey Moore, Board Director of PharmEnable on behalf of new investor MP Healthcare, said,“MPH is dedicated to supporting next generation products and technologies to increase the options available to patients with significant unmet medical needs. We continue to explore novel modalities of treatment, including biotherapeutics, nucleic acid medicines and cell therapies. However, we continue to recognize the clear benefits that small molecules can offer. After an extensive review of available companies and technologies, we concluded that PharmEnable’s robust technology platform was best positioned to effectively explore novel chemical space and deliver the next generation of small molecule therapeutics.”
For more information, contact:
At the Company
Dr Jelena Aleksic, CBO, PharmEnable, firstname.lastname@example.org
Gemma Moses, Communications Consultant, email@example.com, +61 (0) 436 406348
Sue Charles, Charles Consultants, firstname.lastname@example.org +44 (0) 7968 726585
PharmEnable is a Cambridge (UK) based biotech developing the next generation of small molecule drugs, with a focus on novelty, diversity and 3-dimensionality. The company’s interdisciplinary approach integrates advanced medicinal chemistry expertise and cutting-edge AI/computational methods to deliver novel therapeutics for diseases with high clinical need.
PharmEnable’s proprietary drug discovery platform provides a powerhouse for generating novel chemical entities against challenging targets. It models drug targets to identify their key molecular interactions, and map and expand the novel chemical space that can modulate a specific target. Advanced medicinal chemistry expertise guides the development of synthesizable, complex and 3-dimensional small molecules, increasing specificity and reducing off-target effects. Its vision is to reproduce the specificity of biologics in the powerful and scalable form of a small molecule.
PharmEnable’s mission is to deliver life-changing medicines. Its world-class team works across a range of disease areas where drug specificity is a significant challenge, such as cancer and neurological disease. It has a pipeline of wholly owned pre-clinical projects, as well as ongoing co-discovery projects with several pharma and biotech companies, including Sosei Heptares.
The company is backed by life science experienced angle and venture investors including MP Healthcare Venture Management (the venture arm of Mitsubishi Tanabe Pharma Group), Cambridge Enterprise, University of Cambridge Enterprise Funds, Heyford Trust, O2H Ventures, Martlet Capital, Arrowfield Capital and Wren Capital.
For more information see www.pharmenable.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/404903af-db35-4321-9e4d-e2daa84995ca